The Federal Trade Commission’s ongoing investigation into insulin prices has drawn unexpected entities into its web, as subpoenas have been issued by those embroiled in the case, including pharmacy benefit managers, to a diverse array of parties such as McDonald’s and the Defense Department. This legal maneuver comes as the FTC accuses certain parties of artificially inflating insulin prices, leading to subpoenas being cast widely across different sectors.
McDonald’s, having already submitted over 1,300 documents to the FTC, now faces pressure from these pharmacy benefit managers as the scrutiny over insulin pricing intensifies. These legal actions highlight the tangled and far-reaching implications of the FTC’s case, pointing to wider industry practices under examination. The broad sweep of subpoenas suggests that the investigation could have effects on sectors beyond pharmaceuticals.
For further details, see the full article on Law.com.